Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Keytruda (pembrolizumab) is most often covered alongside Bristol Myers Squibb, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Keytruda (pembrolizumab), all published on August 20, 2026.
Last mentioned: 3d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Keytruda (pembrolizumab) is most often covered alongside Bristol Myers Squibb, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Keytruda (pembrolizumab), all published on August 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Keytruda (pembrolizumab). Shared-story counts are live from our verified record — not editorial picks.
A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts.
Keytruda (pembrolizumab) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
